The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Ryuji Takeda - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy and safety of add on 0 1 brimonidine tartrate preserved with sodium chlorite in on treatment japanese normal tension glaucoma patients
Clinical Ophthalmology, 2015Co-Authors: Toyoaki Tsumura, Keiji Yoshikawa, Tairo Kimura, Hirotaka Suzumura, Miwako Kawashima, Mami Nanno, Kiyotaka Ishijima, Ryuji TakedaAbstract:BACKGROUND To evaluate the efficacy and safety of newly formulated brimonidine (0.1% brimonidine tartrate preserved with sodium chlorite: brimonidine) as add-on therapy in on-treatment Japanese normal-tension glaucoma (NTG) patients. METHODS Brimonidine was added to on-treatment NTG patients with intraocular pressures (IOP) of between 13 mmHg and 16 mmHg after three consecutive IOP measurements. The time courses of IOP, Conjunctival Hyperemia, superficial punctate keratitis, and adverse events were examined at 4, 8, and 12 weeks after brimonidine instillation. RESULTS Though 75 of 83 patients (31 males and 52 females; mean age: 63.4±11.6 years) completed the study, six patients discontinued because of side effects and two patients withdrew. The mean IOP after brimonidine addition at week 4 (12.6±1.8 mmHg, P<0.001), week 8 (12.4±1.7 mmHg, P<0.001), and week 12 (12.6±1.8 mmHg, P<0.001) was significantly decreased compared with that before the addition of brimonidine (13.9±1.2 mmHg). No significant changes in superficial punctate keratitis or Conjunctival Hyperemia scores were observed throughout the study. Dizziness, sleepiness, eye pain, and itching (mild to moderate) were noted in five, four, three, and three patients, respectively. CONCLUSIONS The addition of newly formulated brimonidine to on-treatment Japanese NTG patients with IOP of 13-16 mmHg further reduced the levels of IOP with minimal side effects and adverse events.
Toyoaki Tsumura - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy and safety of add on 0 1 brimonidine tartrate preserved with sodium chlorite in on treatment japanese normal tension glaucoma patients
Clinical Ophthalmology, 2015Co-Authors: Toyoaki Tsumura, Keiji Yoshikawa, Tairo Kimura, Hirotaka Suzumura, Miwako Kawashima, Mami Nanno, Kiyotaka Ishijima, Ryuji TakedaAbstract:BACKGROUND To evaluate the efficacy and safety of newly formulated brimonidine (0.1% brimonidine tartrate preserved with sodium chlorite: brimonidine) as add-on therapy in on-treatment Japanese normal-tension glaucoma (NTG) patients. METHODS Brimonidine was added to on-treatment NTG patients with intraocular pressures (IOP) of between 13 mmHg and 16 mmHg after three consecutive IOP measurements. The time courses of IOP, Conjunctival Hyperemia, superficial punctate keratitis, and adverse events were examined at 4, 8, and 12 weeks after brimonidine instillation. RESULTS Though 75 of 83 patients (31 males and 52 females; mean age: 63.4±11.6 years) completed the study, six patients discontinued because of side effects and two patients withdrew. The mean IOP after brimonidine addition at week 4 (12.6±1.8 mmHg, P<0.001), week 8 (12.4±1.7 mmHg, P<0.001), and week 12 (12.6±1.8 mmHg, P<0.001) was significantly decreased compared with that before the addition of brimonidine (13.9±1.2 mmHg). No significant changes in superficial punctate keratitis or Conjunctival Hyperemia scores were observed throughout the study. Dizziness, sleepiness, eye pain, and itching (mild to moderate) were noted in five, four, three, and three patients, respectively. CONCLUSIONS The addition of newly formulated brimonidine to on-treatment Japanese NTG patients with IOP of 13-16 mmHg further reduced the levels of IOP with minimal side effects and adverse events.
Jacek P. Szaflik - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic use of a lotrafilcon A silicone hydrogel soft contact lens as a bandage after LASEK surgery.
Eye & contact lens, 2004Co-Authors: Anna M. Ambroziak, Jacek P. SzaflikAbstract:PURPOSE Soft contact lenses may be used as a bandage after corneal refractive surgery. Silicone hydrogel contact lenses offer the advantage of increased oxygen permeability over conventional hydrogel lenses for this application. To evaluate a silicone hydrogel contact lens as a continuous wear bandage applied after laser-assisted sub-epithelial keratomileusis (LASEK). METHODS We conducted a prospective, open-label, non-randomized clinical trial involving thirty patients treated with unilateral LASEK. Patients were fitted with a lotrafilcon A (Focus NIGHT & DAY; CIBA Vision, Duluth, GA) silicone hydrogel soft contact lens that was worn continuously for 3 to 4 days post-operatively. Lens movement and slitlamp evaluations of Conjunctival Hyperemia 1, 2, and 3 days after surgery (DAS) were recorded, as was the condition of the corneal epithelium after lens removal. Subjective comfort was rated by the patients along with the presence of symptoms or pain. RESULTS Post-blink lens movement was evaluated by investigators as "very good" or "good" in 87% of eyes at 1 DAS, in 73% at 2 DAS, and in 60% at 3 DAS. Conjunctival Hyperemia was assessed as normal or trace in 96% of eyes at 1 DAS, in 76% at 2 DAS, and in 67% at 3 DAS. An average of 80% of eyes showed normal or trace Conjunctival Hyperemia during the trial. The condition of the corneal epithelium after contact lens removal was rated as "very good" in 13% or "good" in 73% of eyes. An average of 77% of subjects reported "very good" or "good" comfort during the trial. Symptoms or pain were rated as "absent" or "mild" by all subjects at 1 DAS and 2 DAS and by 96% at 3 DAS. An average of 99% rated symptoms or pain as either "absent" or "mild" during the trial. CONCLUSIONS The lotrafilcon A lens was found to be an effective and well-tolerated bandage lens after LASEK.
Khalid F Tabbara - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of low dose topical tacrolimus in vernal keratoconjunctivitis
Clinical Ophthalmology, 2016Co-Authors: Samir S Shoughy, Mahmoud O Jaroudi, Khalid F TabbaraAbstract:OBJECTIVE The objective of this study was to evaluate the efficacy and safety of topical low-dose tacrolimus (0.01%) solution in patients with vernal keratoconjunctivitis (VKC). PATIENTS AND METHODS A total of 62 consecutive patients with VKC refractory to conventional treatment were included retrospectively. Tacrolimus 0.01% ophthalmic solution was administered to patients twice daily after discontinuation of all previous topical medications. The duration of treatment ranged from 1 month to 29 months. The clinical symptoms of itching, redness, foreign body sensation, and discharge and the clinical signs of Conjunctival Hyperemia, Conjunctival papillary hypertrophy, limbal infiltration, Trantas dots, and superficial punctate keratopathy were graded as 0 (normal), 1+ (mild), 2+ (moderate), or 3+ (severe). Assessment was carried out before initiation of therapy and on the last visit after treatment. RESULTS There were 62 patients with VKC comprising 49 male and 13 female patients. The median age was 12 years (range: 5-47 years). The mean visual acuity improved from 20/30 to 20/25 following treatment. There was statistically significant improvement in symptoms of itching (P<0.001), redness (P<0.001), foreign body sensation (P<0.001), and discharge (P<0.001). Statistically significant improvement was also observed in clinical signs of Conjunctival Hyperemia (P<0.001), limbal infiltration (P<0.001), Trantas dots (P<0.001), superficial punctate keratopathy (P<0.001), and Conjunctival papillary hypertrophy (P<0.001). The solution form of tacrolimus was well tolerated. None of the patients developed elevation of intraocular pressure, cataract, or infectious keratitis. CONCLUSION Low-dose topical tacrolimus 0.01% solution is effective and safe in the management of patients with refractory VKC.
Yasuhiko Kai - One of the best experts on this subject based on the ideXlab platform.
-
prospective observational post marketing study of tafluprost 0 0015 timolol 0 5 combination ophthalmic solution for glaucoma and ocular hypertension short term efficacy and safety
Ophthalmology and therapy, 2016Co-Authors: Yasutaka Takagi, Hirotaka Osaki, Tomohiro Yamashita, Yasuhiko KaiAbstract:The intraocular pressure (IOP)-lowering effect and safety of tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution (Taf–TFC) were investigated in a real-world clinical setting. A prospective up to 2-year (more than 1 year) observational study has been initiated to collect data on the IOP, Conjunctival Hyperemia score, corneal staining score, and adverse events suffered by patients with glaucoma or ocular hypertension treated at 3 months, and up to 2 years (more than 1 year) after initiating treatment with Taf–TFC. The 3-month findings are reported here. Among 439 patients enrolled at 100 institutions in Japan, most had normal tension glaucoma (45.3%) or primary open angle glaucoma (36.0%). Adverse drug reaction (ADR) occurred in 5.01%. The important ADRs were Conjunctival Hyperemia (five patients), blepharitis (four patients), and punctate keratitis (two patients). Serious adverse reactions occurred in two patients (three events). In 410 patients with data both before and after treatment, baseline mean IOP was 17.5 ± 5.0 mmHg, and it was significantly decreased after 1, 2, and 3 months (all P < 0.05, paired-t test). IOP was significantly reduced in patients switched to Taf–TFC from either prostaglandin or β-blocker monotherapy. IOP also decreased significantly in patients switched from a prostaglandin/timolol fixed combination, but not in patients switched from concomitant use of a prostaglandin analog and a β-blocker. The use of Taf–TFC did not worsen the adherence in most patients. Taf–TFC significantly reduced the IOP in patients with glaucoma or ocular hypertension treated in daily clinical practice with controllable or recoverable ADRs in short period. Taf–TFC was effective regardless of treatment patterns, and particularly, Taf–TFC significantly reduced IOP in cases in which requiring the second line therapy as insufficient of monotherapy. Santen Pharmaceutical Co., Ltd., Osaka, Japan.